Lirum Therapeutics, Inc. Overview
Pro stress-test →Lirum Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. The company's lead candidate, LX-101, is a targeted therapy for oncology and autoimmune diseases, including thyroid eye disease (TED).
Strategic Profile
Pro stress-test →The company was created by Stemline Therapeutics (formerly NASDAQ: STML) management, a veteran team with a proven track record of clinical and regulatory achievement, including FDA and EMA approval and the successful commercial launch of ELZONRIS®, an FDA-designated breakthrough therapy. LX-101 has a differentiated mechanism of action, consisting of a proprietary, precision-engineered IGF-1 variant with high affinity to IGF-1R, coupled to methotrexate, a cytotoxic inhibitor used to treat certain cancers and autoimmune diseases including TED.
Competitive Landscape
Pro stress-test →Cytokinetics, Kiniksa Pharmaceuticals International, and AMO Pharma are competitors of Lirum Therapeutics. Lirum's differentiated mechanism of action targeting IGF-1R with a precision-engineered variant coupled to methotrexate positions it in the broader oncology and autoimmune therapeutics space against other IGF-1R targeted therapies and immunologic treatments for TED.
Industry Context
Lirum Therapeutics, Inc. operates in Biotechnology.
Key facts
Founded: 2021 · Headquarters: New York, US · Employees: 3